medical ozone + methotrexate

Medical ozone + methotrexate is a combination therapy used primarily in the treatment of rheumatoid arthritis (RA) and has also been studied in other inflammatory or autoimmune conditions. Methotrexate is a well-established disease-modifying antirheumatic drug (DMARD) that inhibits dihydrofolate reductase, leading to immunosuppressive and anti-inflammatory effects. Medical ozone refers to a precisely dosed mixture of oxygen and ozone gas administered via routes such as rectal insufflation or autohemotherapy. Ozone acts as a redox modulator, inducing controlled oxidative stress that activates antioxidant defense systems through pathways like Nrf2 activation. The combination enhances clinical efficacy compared to methotrexate alone by increasing anti-inflammatory responses, reducing oxidative stress markers, decreasing proinflammatory cytokines (such as IL-1β and TNF-α), lowering autoantibody levels (e.g., Anti-CCP), improving disability scores, and reducing hepatotoxicity risk associated with methotrexate monotherapy[1][2][3][5][7]. This regimen is not an approved pharmaceutical product but rather an off-label or investigational protocol used in some clinical settings.

Other names

medical ozone and methotrexateMTX + ozonemethotrexate + ozone